Gene interference strategies as a new tool for the treatment of prostate cancer (Q38518046)

3 September 2017

1 reference

title

Gene interference strategies as a new tool for the treatment of prostate cancer (English)

1 reference

3 September 2017

1 reference

1 reference

3 September 2017

1 reference

3 September 2017

Mariarosaria Boccellino

object named as

Mariarosaria Boccellino

0 references

Gaetano Facchini

0 references

Concetta Alaia

1 reference

3 September 2017

Alessia Maria Cossu

series ordinal

1 reference

3 September 2017

Raffaele Piscitelli

series ordinal

1 reference

3 September 2017

Lucio Quagliuolo

series ordinal

1 reference

3 September 2017

language of work or name

1 reference

7 June 2015

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

1 reference

3 September 2017

page(s)

588-605

1 reference

Cancer treatment and survivorship statistics, 2012

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

International variation in prostate cancer incidence and mortality rates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Prostate cancer incidence, clinical stage and survival in relation to obesity: a prospective cohort study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

21 January 2018

Cancer statistics, 2010

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

21 January 2018

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Genetic architecture of cancer and other complex diseases: lessons learned and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Genome-wide association studies in common cancers--what have we learnt?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Linkage of prostate cancer susceptibility loci to chromosome 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

An operational definition of epigenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The dynamics of chromatin remodeling at promoters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

21 January 2018

Epigenetics in cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Clinical practice. Screening for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Overdiagnosis and overtreatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Management of low risk prostate cancer-active surveillance and focal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Role of radiation and androgen deprivation therapy for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Enzalutamide in metastatic prostate cancer before chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Identification of DEK as a potential therapeutic target for neuroendocrine prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The role of IMiDs alone or in combination in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Epigenetics: regulation through repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

mRNA stability in eukaryotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Structural basis for double-stranded RNA processing by Dicer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Short-interfering-RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

RNA interference: biology, mechanism, and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Argonaute proteins: functional insights and emerging roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

RNA interference: from gene silencing to gene-specific therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Prospects of RNA interference therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNAs: genomics, biogenesis, mechanism, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Oncomirs - microRNAs with a role in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Promises and challenges of MicroRNA-based treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNAs and cancer; an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The therapeutic potential of microRNAs in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-34 - a microRNA replacement therapy is headed to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Clinical implications of microRNAs in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Targeting microRNAs in cancer: rationale, strategies and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Oligonucleotide delivery in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

RNA interference in the clinic: challenges and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

PEGylation significantly affects cellular uptake and intracellular trafficking of non-viral gene delivery particles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamer-conjugated polyplex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

RNAi-mediated gene silencing in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Identification of betaArrestin2 as a corepressor of androgen receptor signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The IL-8–Regulated Chemokine Receptor CXCR7 Stimulates EGFR Signaling to Promote Prostate Cancer Growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

PRKC-ζ Expression Promotes the Aggressive Phenotype of Human Prostate Cancer Cells and Is a Novel Target for Therapeutic Intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Amplification and overexpression of vinculin are associated with increased tumour cell proliferation and progression in advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Disrupting tumour blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

On-off system for PI3-kinase-Akt signaling through S-nitrosylation of phosphatase with sequence homology to tensin (PTEN)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Non-genomic loss of PTEN function in cancer: not in my genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

P2X7 mediates ATP-driven invasiveness in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Targeting L1 cell adhesion molecule expression using liposome-encapsulated siRNA suppresses prostate cancer bone metastasis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Preparation of nanobubbles carrying androgen receptor siRNA and their inhibitory effects on androgen-independent prostate cancer when combined with ultrasonic irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Effects of miR-200c on the migration and invasion abilities of human prostate cancer Du145 cells and the corresponding mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-199a-3p inhibits aurora kinase A and attenuates prostate cancer growth: new avenue for prostate cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA-940 suppresses prostate cancer migration and invasion by regulating MIEN1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-26a enhances miRNA biogenesis by targeting Lin28B and Zcchc11 to suppress tumor growth and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in prostate cancer by directly targeting Pin1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA-18a is elevated in prostate cancer and promotes tumorigenesis through suppressing STK4 in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic HOTAIR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Mir-34: a new weapon against cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR 488* inhibits androgen receptor expression in prostate carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

Loss of SNAIL inhibits cellular growth and metabolism through the miR-128-mediated RPS6KB1/HIF-1α/PKM2 signaling pathway in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12020-015-0629-3

A Randomised Phase II Trial Comparing Docetaxel Plus Prednisone with Docetaxel Plus Prednisone Plus Low-Dose Cyclophosphamide in Castration-Resistant Prostate Cancer

21 January 2018

1 reference

12 December 2020

Animal models relevant to human prostate carcinogenesis underlining the critical implication of prostatic stem/progenitor cells

1 reference

12 December 2020

Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms

1 reference

12 December 2020

Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1.

1 reference

12 December 2020

Expression of cutaneous fatty acid-binding protein (C-FABP) in prostate cancer: potential prognostic marker and target for tumourigenicity-suppression

1 reference

12 December 2020

The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators

1 reference

12 December 2020

Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel

1 reference

12 December 2020

microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor

1 reference

12 December 2020

miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions

1 reference

12 December 2020

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

12 December 2020

Prostate cancer epidemiology

1 reference

12 December 2020

Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial

1 reference

12 December 2020

Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness

1 reference

12 December 2020

Design and validation of siRNAs and shRNAs.

1 reference

12 December 2020

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery

1 reference

12 December 2020

Identification of the messenger RNA for human cutaneous fatty acid-binding protein as a metastasis inducer

1 reference

12 December 2020

Prostate cancer prevention by nutritional means to alleviate metabolic syndrome

1 reference

12 December 2020

miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells

1 reference

12 December 2020

Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and enhances cell apoptosis and chemotherapy effects of cisplatin via targeting of DNMT3b and AKT3 in prostate cancer

1 reference

12 December 2020

microRNA-181 promotes prostate cancer cell proliferation by regulating DAX-1 expression

1 reference

12 December 2020

MiR-130b suppresses prostate cancer metastasis through down-regulation of MMP2.

1 reference

12 December 2020

Roots of prostate cancer in African-American men.

1 reference

12 December 2020

10.1007/S12020-015-0629-3

Identifiers

DOI

1 reference

3 September 2017

1 reference